APA

Merlano M. C., Merlotti A. M., Licitra L., Denaro N., Fea E., Galizia D., Di Maio M., Fruttero C., Curcio P., Vecchio S., Russi E. G. & Corvò R. (2018). Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide. : Clinical and translational radiation oncology.

Chicago

Merlano Marco C, Merlotti Anna M, Licitra Lisa, Denaro Nerina, Fea Elena, Galizia Danilo, Di Maio Massimo, Fruttero Claudia, Curcio Paola, Vecchio Stefania, Russi Elvio G and Corvò Renzo. 2018. Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide. : Clinical and translational radiation oncology.

Harvard

Merlano M. C., Merlotti A. M., Licitra L., Denaro N., Fea E., Galizia D., Di Maio M., Fruttero C., Curcio P., Vecchio S., Russi E. G. and Corvò R. (2018). Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide. : Clinical and translational radiation oncology.

MLA

Merlano Marco C, Merlotti Anna M, Licitra Lisa, Denaro Nerina, Fea Elena, Galizia Danilo, Di Maio Massimo, Fruttero Claudia, Curcio Paola, Vecchio Stefania, Russi Elvio G and Corvò Renzo. Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide. : Clinical and translational radiation oncology. 2018.